The protein DIIIC‐2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV‐2

Lázaro Gil; Ernesto Marcos; Alienys Izquierdo; Laura Lazo; Iris Valdes; Peris Ambala; Lucy Ochola; Rikoi Hitler; Edith Suzarte; Mayling Alvarez; Prisilla Kimiti; James Ndung'u; Thomas Kariuki; María Guadalupe Guzmán; Gerardo Guillén; Lisset Hermida

doi:10.1038/icb.2014.63

journal article Sep 02, 2014

The protein DIIIC‐2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV‐2

Lázaro Gil

Ernesto Marcos Alienys Izquierdo Laura Lazo

Iris Valdes

Peris Ambala Lucy Ochola Rikoi Hitler Edith Suzarte

Mayling Alvarez Prisilla Kimiti James Ndung'u Thomas Kariuki María Guadalupe Guzmán Gerardo Guillén Lisset Hermida

Immunology & Cell Biology Vol. 93 No. 1 pp. 57-66 · Wiley

View at Publisher Save 10.1038/icb.2014.63

Abstract

Previously, we reported the ability of the chimeric protein DIIIC‐2 (domain III of the dengue envelope protein fused to the capsid protein of dengue‐2 virus), to induce immunity and protection in mice, when it is highly aggregated with a non‐defined oligodeoxynucleotide (ODN) and adjuvanted in alum. In this work, three different defined ODNs were studied as aggregating agents. Our results suggest that the nature of the ODN influences the capacity of protein DIIIC‐2 to activate cell‐mediated immunity in mice. Consequently, the ODN 39M was selected to perform further experiments in mice and nonhuman primates. Mice receiving the preparation 39M‐DIIIC‐2 were solidly protected against dengue virus (DENV) challenge. Moreover, monkeys immunized with the same preparation developed neutralizing antibodies, as measured by four different neutralization tests varying the virus strains and the cell lines used. Two of the immunized monkeys were completely protected against challenge, whereas the third animal had a single day of low‐titer viremia. This is the first work describing the induction of short‐term protection in monkeys by a formulation that is suitable for human use combining a recombinant protein from DENV with alum.

Topics

No keywords indexed for this article. Browse by subject →

References

44

[1]

10.4269/ajtmh.2009.80.846

[2]

10.1016/j.ijantimicag.2010.06.018

[3]

10.1093/oxfordjournals.aje.a113932

[4]

10.1016/s1201-9712(99)90033-4

[5]

10.1086/649916

[6]

10.1016/s0140-6736(12)61428-7

[7]

10.1007/s00705-012-1471-z

[8]

10.1016/j.virol.2009.08.029

[9]

10.1016/j.intimp.2006.06.001

[10]

10.1016/j.vaccine.2011.03.040

[11]

10.4049/jimmunol.166.4.2372

[12]

10.1002/1521-4141(200107)31:7<2154::aid-immu2154>3.0.co;2-u

[13]

10.1016/j.vaccine.2008.11.106

[14]

10.1128/cvi.00191-09

[15]

10.1128/cvi.00208-07

[16]

10.1016/j.virol.2009.06.037

[17]

10.1128/jvi.01826-10

[18]

10.1128/jvi.06871-11

[19]

10.1016/j.virol.2012.03.003

[20]

10.1128/jvi.02298-12

[21]

10.1016/j.ijid.2009.06.017

[22]

10.1128/cvi.00382-10

[23]

10.1016/j.antiviral.2012.04.006

[24]

10.1099/vir.0.037721-0

[25]

10.1128/jvi.78.6.2701-2710.2004

[26]

10.4049/jimmunol.181.9.5865

[27]

10.1016/j.vaccine.2011.03.038

[28]

10.1093/infdis/jir012

[29]

10.1016/j.vaccine.2006.01.036

[30]

10.1016/j.antiviral.2008.06.005

[31]

10.1016/j.vaccine.2010.01.022

[32]

10.1016/j.vaccine.2005.03.042

[33]

10.1016/s0140-6736(13)60754-0

[34]

10.1128/jvi.78.9.4761-4775.2004

[35]

10.1006/viro.2002.1462

[36]

10.1016/j.virol.2009.10.023

[37]

Alvarez M "Improved dengue virus plaque formation on BHK21 and LLCMK2 cells: evaluation of some factors" Dengue Bull (2005)

[38]

10.4269/ajtmh.1958.7.561

[39]

10.4269/ajtmh.1995.52.241

[40]

10.4269/ajtmh.2003.69.6_suppl.0690005

[41]

10.1016/0042-6822(88)90677-0

[42]

10.1007/s00705-009-0350-8

[43]

10.1089/vim.2008.0063

[44]

10.1128/jcm.22.2.250-254.1985

Cited By

34

The tetravalent formulation of domain III‐capsid proteins recalls memory B‐ and T‐cell responses induced in monkeys by an experimental dengue virus infection

Lázaro Gil, Laura Lazo · 2017

Clinical & Translational Immuno...

Metrics

34

Citations

44

References

Details

Published: Sep 02, 2014
Vol/Issue: 93(1)
Pages: 57-66
License: View

Authors

L

Lázaro Gil

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

E

Ernesto Marcos

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

A

Alienys Izquierdo

Virology Department, Tropical Medicine Institute ‘Pedro Kourí’, PAHO/WHO Collaborating Center for the study of Dengue and its vector Havana Cuba

L

Laura Lazo

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

I

Iris Valdes

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

P

Peris Ambala

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

L

Lucy Ochola

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

R

Rikoi Hitler

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

E

Edith Suzarte

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

M

Mayling Alvarez

Virology Department, Tropical Medicine Institute ‘Pedro Kourí’, PAHO/WHO Collaborating Center for the study of Dengue and its vector Havana Cuba

P

Prisilla Kimiti

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

J

James Ndung'u

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

T

Thomas Kariuki

Department of Tropical and Infectious Diseases, Institute of Primate Research, National Museum of Kenya, WHO Collaborating Center Nairobi Kenya

M

María Guadalupe Guzmán

Virology Department, Tropical Medicine Institute ‘Pedro Kourí’, PAHO/WHO Collaborating Center for the study of Dengue and its vector Havana Cuba

G

Gerardo Guillén

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

L

Lisset Hermida

Vaccines Division, Center for Genetic Engineering and Biotechnology Havana Cuba

Cite This Article

Lázaro Gil, Ernesto Marcos, Alienys Izquierdo, et al. (2014). The protein DIIIC‐2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV‐2. Immunology & Cell Biology, 93(1), 57-66. https://doi.org/10.1038/icb.2014.63

The protein DIIIC‐2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV‐2

You May Also Like